Peritoneal Cancer Study
GOG 0212: A Randomized Phase III trial of maintenance Chemotherapy comparing 12 monthly cycles of single agent Paclitaxel or Xyotax (CT-2103) vs. no treatment until documented relapse in women with advanced ovarian or primary Peritoneal Cancer
Protocol ID
Protocol Description
The purpose of this study is to examine whether women with advanced ovarian cancer who have no evidence of disease after the completion of initial chemotherapy live longer if a specific treatment program is continued once a month for 12 months versus stopping all chemotherapy until there is evidence of recurrence of the disease process. There are three arms to this study: two different chemotherapy regimen arms and one arm which will receive no further treatment.
Eligibility Criteria
Women with ovarian or primary peritoneal cancer that has been confirmed by surgery.
Primary Investigator(s)
- Veena John, MD